Differences in second trimester risk estimates for trisomy 21 between Maglumi X3/Preaccu and Immulite/Prisca systems

Differences in second trimester risk estimates for trisomy 21 between Maglumi X3/Preaccu and Immulite/Prisca systems

Maternal serum alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG) or free β-HCG, and unconjugated estriol (uE3) concentrations are used to screen trisomy 21 in the second trimester. The performance of different analytical platforms has an impact on individual risk estimates. The aim of this...

Full description

Saved in:
Bibliographic Details
Main Authors: Üstündağ Yasemin, Huysal Kağan, Yeşil Meryem Rümeysa
Format: Article
Language:English
Published: De Gruyter 2024-12-01
Series:Türk Biyokimya Dergisi
Subjects:
method comparison
maglumi x3/preaccu system
second trimester down screening
risk assessment
immulite/prisca system
Online Access:https://doi.org/10.1515/tjb-2023-0203
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Maternal serum alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG) or free β-HCG, and unconjugated estriol (uE3) concentrations are used to screen trisomy 21 in the second trimester. The performance of different analytical platforms has an impact on individual risk estimates. The aim of this study is to compare the multiple of median (MoM) values and risk estimates generated by Maglumi X3 analyzer/Preaccu software with the Immulite 2000 XPi device/Prisca software.
ISSN:1303-829X

Similar Items